Catalent signs combined cell development and Ab manufacturing deal
Catalent has signed a cell line development deal with Nascent Biologics, further underlining its interest in biologics-focused contracting.
Archives for April 16, 2012
Novo Nordisk warns FDA of biosimilar delivery safety fears
Novo Nordisk has told the FDA allowing alternative delivery devices for biosimilars creates “significant safety implications”.